Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Medical
Near Term Catalysts Should Propel Synergy's Share Price
Feb 19 2014 @ 08:00
Synergy Pharmaceuticals (SGYP) focuses on the development of drugs to treat gastrointestinal disorders and diseases...
Progenics Pharma Has Two Important Upcoming Catalysts
Jan 02 2014 @ 11:22
Progenics has two upcoming catalysts: Progenics is expecting to announce data from its Phase II PSMA ADC trial at...
Following Smart Money: The Baker Brothers LLC Investments In 2013 And Beyond
Dec 20 2013 @ 11:57
Perhaps the most important buying indicator for a developmental pharma is who is buying the stock. At stockmatusow...
XOMA Corporation Looks Poised For Technical Break-Out
Dec 20 2013 @ 08:10
XOMA Corporation Looks Poised For Technical Break-Out Reasons Break-Out on $XOMA; 1. 52 week high reached on...
OncoNova To Present Data At Ash Conference
Nov 06 2013 @ 10:48
OncoNova (ONTX) will present overall results from the Phase 2 trial of oral rigosertib in transfusion-dependent...
Confusion Along With Major Catalyst Makes Onconova Therapeutics An Attractive Entry Heres
Oct 28 2013 @ 14:43
There seems to be confusion over the P3 trial where people think the company has bad data in hand, based on what...
Sunshine Heart Inc. Could Revolutionize Heart Failure Treatment
Oct 22 2013 @ 07:39
Recent developments in the medical device industry have paved the way for some strong achievements in many different...
Phase 3 Hepatitis C Data For Enanta Pharma Expected November 3rd
Oct 18 2013 @ 03:30
At StockMatusow we strive to identify companies that we feel have the potential for both short and long term gains...
Halozyme Therapeutics advances pancreatic cancer treatment exploring the use of the agent PEGPH20 (PEGylated Recombinant Human Hyaluronidase)
Oct 10 2013 @ 10:26
Halozyme (NASDAQ: HALO) has a potential breakthrough in new therapeutic combination represents how pancreatic cancer...
Bullish Chart Technicals: $ACRX
Oct 04 2013 @ 13:34
Below, I show the AcelRx (NASDAQ: ACRX) charts and give some commentary why I believe it will hit $12 soon. Chart 1...
